NDLI: Immune response and safety to inactivated COVID-19 vaccine: a comparison between people living with HIV and HIV-naive individuals

Content Provider	Springer Nature : BioMed Central
Author	Zou, Shi Wu, Mengmeng Ming, Fangzhao Wu, Songjie Guo, Wei Marley, Gifty Xing, Zhongyuan Zhang, Zhiyue Zeng, Minxia Sun, Chao Zhang, Jianfeng Tang, Weiming Liang, Ke
Abstract	Background Multi-types COVID-19 vaccines have shown safety and efficacy against COVID-19 in adults. Although current guidelines encourage people living with HIV (PLWH) to take COVID-19 vaccines, whether their immune response to COVID-19 vaccines is distinct from HIV-free individuals is still unclear. Methods Between March to June 2021, 48 PLWH and 40 HNC, aged 18 to 59 years, were enrolled in the study in Wuchang district of Wuhan city. All of them received inactivated COVID-19 vaccine (Sinopharm, WIBP-CorV, Wuhan Institute of Biological Products Co. Ltd) at day 0 and the second dose at day 28. The primary safety outcome was the combined adverse reactions within 7 days after each injection. The primary immunogenicity outcomes were SARS-CoV-2 neutralizing antibodies (nAbs) responses by chemiluminescence and total specific IgM and IgG antibodies responses by ELISA and colloidal gold at baseline (day 0), day 14, day 28, day 42, and day 70. Results In total, the study included 46 PLWH and 38 HNC who finished 70 days’ follow-up. The frequency of adverse reactions to the first and second dose was not different between PLWH (30% and 11%) vs. HNC (32% and 24%). NAbs responses among PLWH peaked at day 70, while among HNC peaked at day 42. At day 42, the geometric mean concentration (GMC) and seroconversion rate of nAbs among PLWH were 4.46 binding antibody units (BAU)/mL (95% CI 3.18–5.87) and 26% (95% CI 14–41), which were lower than that among HNC [GMC (18.28 BAU/mL, 95% CI 10.33–32.33), seroconversion rate (63%, 95% CI 44–79)]. IgG responses among both PLWH and HNC peaked at day 70. At day 70, the geometric mean ELISA units (GMEU) and seroconversion rate of IgG among PLWH were 0.193 ELISA units (EU)/mL (95% CI 0.119–0.313) and 51% (95% CI 34–69), which was lower than that among HNC [GMEU (0.379 EU/mL, 95% CI 0.224–0.653), seroconversion rate (86%, 95% CI 64–97)]. There were no serious adverse events. Conclusions Early humoral immune response to the inactivated COVID-19 vaccine was weaker and delayed among the PLWH population than that among HNC. This observation remained consistent regardless of a high CD4 count with effective antiretroviral therapy.
Related Links	https://aidsrestherapy.biomedcentral.com/counter/pdf/10.1186/s12981-022-00459-y.pdf
Ending Page	8
Page Count	8
Starting Page	1
File Format	HTM / HTML
ISSN	17426405
DOI	10.1186/s12981-022-00459-y
Journal	AIDS Research and Therapy
Issue Number	1
Volume Number	19
Language	English
Publisher	BioMed Central
Publisher Date	2022-07-05
Access Restriction	Open
Subject Keyword	Infectious Diseases Virology Inactivated COVID-19 vaccine PLWH Humoral immune response Antibody neutralization
Content Type	Text
Resource Type	Article
Subject	Molecular Medicine Virology Pharmacology (medical)
Journal Impact Factor	2.1/2023
5-Year Journal Impact Factor	2.4/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Correction: Immune response and safety to inactivated COVID-19 vaccine: a comparison between people living with HIV and HIV-naive individuals

Adverse events of inactivated COVID-19 vaccine in HIV-infected adults

Humoral immune response to inactivated COVID-19 vaccination at the 3rd month among people living with HIV

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV.

Six-month humoral immune response to inactivated COVID-19 vaccine among people living with HIV

Serum Metabolic Correlates of the Antibody Response in Subjects Receiving the Inactivated COVID-19 Vaccine.

Correction: Humoral immune response to inactivated COVID-19 vaccination at the 3rd month among people living with HIV

Safety and Immunogenicity of the Inactivated COVID-19 Vaccine Booster in People Living with HIV in China.

Reduced T-cell response following a third dose of SARS-CoV-2 vaccine in infection-naïve people living with HIV.

Immune response and safety to inactivated COVID-19 vaccine: a comparison between people living with HIV and HIV-naive individuals

Similar Documents

Correction: Immune response and safety to inactivated COVID-19 vaccine: a comparison between people living with HIV and HIV-naive individuals

Adverse events of inactivated COVID-19 vaccine in HIV-infected adults

Humoral immune response to inactivated COVID-19 vaccination at the 3rd month among people living with HIV

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV.

Six-month humoral immune response to inactivated COVID-19 vaccine among people living with HIV

Serum Metabolic Correlates of the Antibody Response in Subjects Receiving the Inactivated COVID-19 Vaccine.

Correction: Humoral immune response to inactivated COVID-19 vaccination at the 3rd month among people living with HIV

Safety and Immunogenicity of the Inactivated COVID-19 Vaccine Booster in People Living with HIV in China.

Reduced T-cell response following a third dose of SARS-CoV-2 vaccine in infection-naïve people living with HIV.

Immune response and safety to inactivated COVID-19 vaccine: a comparison between people living with HIV and HIV-naive individuals